405230-79-7

Basic information

• Product Name: Pyridine, 2-chloro-5-fluoro-, 1-oxide (9CI)
• Synonyms: Pyridine, 2-chloro-5-fluoro-, 1-oxide (9CI);2-chloro-5-fluoro-1-oxidopyridin-1-ium
• CAS NO: 405230-79-7
• Molecular Formula: C₅H₃ClFNO
• Molecular Weight: 147.5348232
• Product Categories: PYRIDINE
• Mol File: 405230-79-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 98-100℃
• Boiling Point: 311.3±22.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.34±0.10(Predicted)
• CAS DataBase Reference: Pyridine, 2-chloro-5-fluoro-, 1-oxide (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-chloro-5-fluoro-, 1-oxide (9CI)(405230-79-7)
• EPA Substance Registry System: Pyridine, 2-chloro-5-fluoro-, 1-oxide (9CI)(405230-79-7)

Safety Data

• Hazardous Substances Data: 405230-79-7(Hazardous Substances Data)

Usage

General Description

Pyridine, 2-chloro-5-fluoro-, 1-oxide (9CI) is a chemical compound with the molecular formula C5H3ClFNO. It is also known by the name 2-Chloro-5-fluoropyridine N-oxide. Pyridine, 2-chloro-5-fluoro-, 1-oxide (9CI) is a pale yellow to light brown crystalline solid with a melting point of 79-81°C. It is mainly used as a reagent in organic synthesis and pharmaceutical research. Pyridine, 2-chloro-5-fluoro-, 1-oxide (9CI) is known for its potential application in the development of new drugs and as a building block in the synthesis of pharmaceutical intermediates. It is important to handle this chemical with care and follow proper safety precautions due to its potential health hazards.

Upstream product

• 31301-51-6 2-chloro-5-fluoropyridine 

Downstream Products

• 1449515-83-6 6-chloro-N3-methylpyridine-3,4-diamine 
• 1369769-03-8 6-chloro-3-fluoropyridin-2-ol 
• 1334411-83-4 4-bromo-2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 1334411-84-5 4-chloro-7-fluoro-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine 
• 1334407-23-6 N-(2-(2,6-dichlorophenyl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-yl)cyclopropanecarboxamide 
• 1334407-22-5 2-(2,6-dichlorophenyl)-N-(2,6-dimethylpyrimidin-4-yl)-7-fluoro-1H-imidazo[4,5-c]pyridin-4-amine 
• 405231-08-5 4-chloro-7-fluoro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)imidazo[4,5-c]pyridine 
• 405230-90-2 4-amino-2-chloro-5-fluoro-3-nitropyridine 
• 405230-93-5 2-chloro-3,4-diamino-5-fluoropyridine 
• 405230-86-6 2-chloro-5-fluoro-4-nitraminopyridine 
• 405230-97-9 4-chloro-7-fluoro-1H-imidazo[4,5-c]pyridine 
• 89510-90-7 4-amino-2-chloro-5-fluoropyridine 
• 202806-40-4 3-deaza-3-fluoro-adenosine 
• 405230-80-0 2-chloro-5-fluoro-4-nitropyridine-1-oxide 

Relevant articles and documents

BCAT MODULATION

This disclosure relates to, in part, the treatment of an organic acidemia in a subject in need thereof via administration of a therapeutically effective amount of compounds that inhibit BCAT2. The disclosure also relates to, in part, methods for identifying a candidate compound for treatment of organic acidemias.

Design, synthesis and biological evaluation of novel substituted purine isosters as EGFR kinase inhibitors, with promising pharmacokinetic profile and in vivo efficacy

Novel substituted purine isosters, were designed and synthesized as potential inhibitors of the Epidermal Growth Factor Receptor (EGFR). The compounds were rationally designed through bioisosteric replacement of the central quinazoline core of lapatinib, an approved drug that inhibits both EGFR and HER2, another important member of this family of receptors. The new target molecules were evaluated as inhibitors of receptor phosphorylation at the cellular level, for their direct inhibitory action on the intracellular receptor kinase domain and for their cytotoxicity against the non-small cell lung cancer cell line A549 and breast cancer HCC1954, cell lines which are associated with overexpression of EGFR and HER2, respectively. The most potent derivatives were further studied for their cellular uptake levels and in vivo pharmacokinetic properties. One compound (23)displayed a noteworthy pharmacokinetic profile, and higher intracellular accumulation in comparison to lapatinib in the A549 cells, possibly due to its higher lipophilicity. This lead compound (23)was assessed for its efficacy in an EGFR positive xenograft model, where it successfully inhibited tumor growth, with a similar efficacy with that of lapatinib and with minimal phenotypic toxicity.

NRF2 REGULATORS

The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.